Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.

Pujade-Lauraine, Eric; Fujiwara, Keiichi; Ledermann, Jonathan A; Oza, Amit M; Kristeleit, Rebecca; Ray-Coquard, Isabelle-Laure; Richardson, Gary E; Sessa, Cristiana; Yonemori, Kan; Banerjee, Susana; Leary, Alexandra; Tinker, Anna V; Jung, Kyung Hae; Madry, Radoslaw; Park, Sang-Yoon; Anderson, Charles K; Zohren, Fabian; Stewart, Ross A; Wei, Caimiao; Dychter, Samuel S; Monk, Bradley J

Pujade-Lauraine, Eric; Fujiwara, Keiichi; Ledermann, Jonathan A; Oza, Amit M; Kristeleit, Rebecca; Ray-Coquard, Isabelle-Laure; Richardson, Gary E; Sessa, Cristiana; Yonemori, Kan; Banerjee, Susana; Leary, Alexandra; Tinker, Anna V; Jung, Kyung Hae; Madry, Radoslaw; Park, Sang-Yoon; Anderson, Charles K; Zohren, Fabian; Stewart, Ross A; Wei, Caimiao; Dychter, Samuel S; Monk, Bradley J.

Affiliation

Pujade-Lauraine E; ARCAGY-GINECO, Paris, France. Electronic address: epujade@arcagy.org.
Fujiwara K; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
Ledermann JA; University College London Cancer Institute, London, UK; University College London Hospitals, London, UK.
Oza AM; Princess Margaret Cancer Centre, Toronto, ON, Canada.
Kristeleit R; University College London Cancer Institute, London, UK; University College London Hospitals, London, UK.
Ray-Coquard IL; Centre Léon Bérard, Service de Cancérologie Médicale, Université Claude Bernard Lyon 1, Lyon, France; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Paris, France.
Richardson GE; Cabrini Hospital, Department of Medical Oncology, Malvern, VIC, Australia.
Sessa C; Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland.
Yonemori K; Department of Breast and Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Banerjee S; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.
Leary A; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Paris, France; Gustave Roussy Cancer Campus, Villejuif, France.
Tinker AV; BC Cancer-Vancouver, Vancouver, BC, Canada.
Jung KH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea.
Madry R; Poznan University of Medical Sciences, Department of Oncology, Poznan, Poland.
Park SY; Center for Uterine Cancer, National Cancer Center, Ilsandong-gu, Goyang-si, Gyeonggi-do, South Korea.
Anderson CK; Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA.
Zohren F; Pfizer Oncology, Cambridge, MA, USA.
Stewart RA; Pfizer Oncology, San Diego, CA, USA.
Wei C; Pfizer, Global Biometrics and Data Management, Groton, CT, USA.
Dychter SS; Pfizer Oncology, San Diego, CA, USA.
Monk BJ; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ, USA.

Lancet Oncol ; 22(7): 1034-1046, 2021 07.

Article de En | MEDLINE | ID: mdl-34143970

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'ovaire / Protocoles de polychimiothérapie antinéoplasique / Composés du platine / Anticorps monoclonaux humanisés / Inhibiteurs de points de contrôle immunitaires Type d'étude: Clinical_trials Limites: Aged / Female / Humans / Middle aged Langue: En Journal: Lancet Oncol Sujet du journal: NEOPLASIAS Année: 2021 Type de document: Article

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google